Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid Leukemia

Summary

The primary aim of this innovative immunotherapy using WT1/hTERT/Survivin-loaded DCs is to determine whether this novel DC vaccination is safe and can significantly prevent clinical relapse and increase survival of acute myeloid leukemia (AML) patients by eradicating minimal residual disease, while maintaining its safety profile in this phase I trial.

Timeline

Start

2021-07-01

Primary completion

2026-07-01

Completion

2026-07-01

Drugs

Indications